Overview

A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)

Status:
Completed
Trial end date:
2019-08-29
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in participants with SLE. The study will last about 79 days for each participant.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Nektar Therapeutics
Collaborators:
Eli Lilly and Company
Nektar Therapeutics